Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
World game at war: why some European nations have threatened a World Cup boycott 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
SOUTH SAN FRANCISCO, Calif., May 04, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on May 1, 2018, the compensation committee of the Company’s board of directors granted four new employees options to purchase an aggregate of 14,250 shares of the Company’s common stock with a per share exercise price of $45.20, the closing trading price on the grant date, and restricted stock units for an aggregate of 9,400 shares of the Company’s common stock. All of the above-described awards were made under the Company’s 2017 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Company has reserved an aggregate of 300,000 shares of its common stock (including the shares underlying the stock option and restricted stock unit award described above) for issuance under the Plan, which was approved by the Company’s board of directors in January 2017.
About GBT
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
[email protected]
Julie Normart (media)
W2O pure
415-946-1087
[email protected]
